• 
Dutch Biotech selects Maybridge Fragment Library

News & Views

Dutch Biotech selects Maybridge Fragment Library

Oct 27 2012

Thermo Fisher Scientific has been selected to supply compounds from its Maybridge Ro3 2500 Diversity Fragment Library to a leading fragment-based drug discovery firm based in the Netherlands.

ZoBio, a spin-off of Leiden University, focuses on the development and commercialisation of biophysical technologies that enable new approaches to drug development; Dr. Edward Zartler, CEO of Quantum Tessera Consulting LLC who was consulted to identify and purchase the most suitable targeted screening library for ZoBio’s structure-based discovery needs, chose the Maybridge collection for its broad range of pharmacophores.

ZoBio has begun using the Maybridge library to design its own compound collection targeted to an epigenetic drug target. The collection will enable ZoBio’s customers to pursue and expedite fragment-based drug delivery.

“The entire Maybridge 2500 collection is Rule of Three (Ro3)-compliant and exceptionally well-curated with greater than 95 percent purity assurance and guaranteed solubility of 1 mM in aqueous phosphate buffer solution,” said Dr. Zartler.

ZoBio assembled its 250 fragment library by virtually screening against a pharmacophore model. It was easy to triage and accept molecules because Maybridge has already done a tremendous job of removing chemically suspect molecules. The breadth of chemical diversity and the depth of compounds to choose from allowed them to rapidly put together a robust, diverse and structure activity relationship-compliant library,” he added.
 


Digital Edition

LMUK 49.7 Nov 2024

November 2024

News - Research & Events News   - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...

View all digital editions

Events

MEDICA 2024

Nov 11 2024 Dusseldorf, Germany

FILTECH

Nov 12 2024 Cologne, Germany

Intech

Nov 12 2024 Tel Aviv, Israel

analytica China

Nov 18 2024 Shanghai, China

Pharma Asia

Nov 20 2024 Karachi, Pakistan

View all events